Search

Your search keyword '"Lotan, Tamara L"' showing total 896 results

Search Constraints

Start Over You searched for: Author "Lotan, Tamara L" Remove constraint Author: "Lotan, Tamara L"
896 results on '"Lotan, Tamara L"'

Search Results

103. Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions

104. Supplemental Table 1 from Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer

106. Supplementary Figure 2 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

107. Supplementary Figure S5 from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer

108. Supplementary Figure S4 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas

109. Data from PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

110. Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer

111. Table S6 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer

112. 'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer

113. Supplementary tables from Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer

114. Supplementary Table 1 from PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

115. Supp Tables from MSH2 Loss in Primary Prostate Cancer

116. Supp Fig S2 from MSH2 Loss in Primary Prostate Cancer

117. Supplementary Figure 1 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

118. supplemental legend from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer

119. Data from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas

120. Supplementary figures from Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer

121. supp Tables from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

122. Supplementary Table S1 from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer

123. supplemental figure legend and Materials and Methods from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas

124. Supplementary Table 1 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

125. Sup Fig 1 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

126. Supplementary Data from Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer

127. Sup Fig 2 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy

128. Supplementary Data from CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer

139. Impact of concurrent tumor events on the prostate cancer outcomes of germline BRCA2 mutation carriers

141. Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

142. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.

143. Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer

148. mTORCI loss impairs epidermal adhesion via TGF-[beta]/Rho kinase activation

149. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions

150. Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8

Catalog

Books, media, physical & digital resources